Introduction
============

Minimally invasive left ventricular assist device (LVAD) implantation has proven in the past years that it is a superior technique to conventional LVAD implantation.[@JR150190crc-1] The less invasive procedure has several benefits such as reducing right heart failure, reducing wound infection, and shorter duration of procedure as well shorter intrahospital stay for the patient. Also, it is associated with a diminished usage of blood products due to less bleeding complications.[@JR150190crc-2] [@JR150190crc-3]

Surgery on Jehovah\'s witnesses is always a challenge for surgeons, too. This society has remarkably grown and counts over 7 million followers worldwide today. According to Jehovah\'s witnesses\' interpretation of the Bible, it is prohibited to ingest blood of any kind. It is up to the conscious of each individual to accept transfusions of fractionations of the primary components.[@JR150190crc-4] [@JR150190crc-5] Especially cardiac surgeries have a higher risk for blood loss with the need of blood transfusions. This creates a difficult situation for the patient and for the doctor who is legally bound to provide best medical care to every patient. Therefore, a minimally invasive LVAD implantation technique was used when a Jehovah\'s witness was referred to our clinic with end-stage heart failure.

Results
=======

We present a 48-year-old patient (175 cm, 75 kg, body mass index 24.5 kg/m^2^) who was admitted to our clinic due to acute decompensation of dilative cardiomyopathy. The patient presented the signs of hypotonic pressures, dyspnoea, tachycardia, and acrocyanosis.

Echocardiography was performed and showed a severe decrease of left ventricular ejection function (13% \[Simpson\]) and a reduced right ventricular function as well as a second-degree mitral valve insufficiency. Laboratory parameters showed decreased liver and renal function. Due to respiratory insufficiency, noninvasive ventilation became necessary. The history of the patient showed a possible case of viral myocarditis 18 years ago. Dilated cardiomyopathy was diagnosed 8 years ago. After multiple attempts to medically stabilize the condition of the patient, the case was presented to the cardiovascular surgery department ([Fig. 1](#FI150190crc-1){ref-type="fig"}). In an interdisciplinary discussion, it was decided to implant a mechanical assist device. The patient was a Jehovah\'s witness and approved LVAD implantation but declined the use of any blood products even in emergency situations.
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The procedure was performed with our minimally invasive LVAD implantation technique, which combines an upper ministernotomy with an anterolateral thoracotomy.[@JR150190crc-1] Via anterolateral thoracotomy, the sewing ring of the HVAD (HeartWare) was sewed onto the beating heart. The venous line of the heart--lung machine was placed in the femoral vein. The arterial line was placed via ministernotomy to the ascending aorta. After starting of the heart--lung machine, the assist device was placed into the left ventricle. The outflow graft cannula was tunneled through the pleural cavity and sewed onto the ascending aorta. The weaning from the heart--lung machine was completely uneventful. The procedure was performed without any use of blood products including thrombocytes, fresh frozen plasma, or any other coagulation factors ([Fig. 2](#FI150190crc-2){ref-type="fig"}).
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Laboratory parameters showed preoperative blood hemoglobin (Hb) and hematocrit (Hct) just before the operation of 11.3 g/dL and 33.1%, respectively. Mean Hb during the preoperative hospital stay (16 days) was 9 g/dL with standard deviation (SD) of 0.50 mg/dL and mean Hct was 35% with SD of 1.49%. The first parameters obtained immediately after the operation were 9.3 g/dL and 27% for Hb and Hct, respectively. Postoperative data showed mean Hb of 8.53 g/dL with SD of 1.79 g/dL and mean Hct of 25.70% with SD of 5.21%. The patient was discharged after a completely uneventful intrahospital stay on postoperative day 17. Hb and Hct on the day of discharge were 13.1 g/dL and 37.5%, respectively. Mean Hb of 9.31 g/dL with SD of 2.11 g/dL and mean Hct of 27.87% with SD of 6.01% were calculated from data obtained during the total hospital stay of 35 days ([Fig. 3](#FI150190crc-3){ref-type="fig"}).
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Discussion
==========

The reduction of blood loss is a goal for all surgeries. Especially LVAD implantations are considered to be prone to high blood loss and high usage of coagulation factors. Even though tested multiple times before transfusion, blood products still contain risks for allergic reactions to transfusion of infectious diseases. Furthermore, economic costs for blood products are one of the major contributors for the high costs of LVAD implantation. Therefore, the reduction of usage of blood products is one of the keys to lowering the cost for LVAD programs.

Minimally invasive LVAD implantation, first described by our group, has already proven itself to be associated with several positive effects. It has been shown that the total number of blood transfusion was reduced by implanting an LVAD via a minimally invasive technique.[@JR150190crc-1] [@JR150190crc-2] [@JR150190crc-3] Now, it is proven that it is even possible to implant an LVAD minimally invasively without the use of any blood products. As devices become smaller, incision sites should reduce in size as well.

Despite the excellent result of this procedure, the surgical approach as well as the risk and consequences of blood loss must be intensively discussed with the patient. In our case, the patient accepted blood transfusions only in the case of imminent death due to blood loss. Although a case of heart transplantation in a Jehovah\'s witness has been described,[@JR150190crc-6] the therapeutic goal of our patient is destination therapy with LVAD support. In case of reoperation, our strategy is minimally invasive LVAD exchange without the use of the heart--lung machine.[@JR150190crc-7]

Conclusion
==========

It has been proven that minimally invasive LVAD implantation without blood transfusion is possible. This benefits not only Jehovah\'s witness patients but also all patients in the need of a ventricular assist device. Yet, the course of the patients has to be kept in mind, which may require further interventions with the need of blood transfusion. Therefore, LVAD implantation in Jehovah\'s witnesses should be a critically evaluated procedure.
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